Melanomas metastasizing to different organs often display heterogenous responses to therapies such as BRAF inhibitor or anti-PD-1 (aPD-1) immunotherapy. This heterogeneity of responses may be due to strictly tumor cell-intrinsic biological differences or more likely co-adaptation of the tumors with organ site-specific microenvironments. However, most patient-centric studies of metastatic melanoma biology and/or therapeutic responses are limited to one tumor per patient, with a predominance of tumors from more accessible sites such as the skin. Thus, there is a dearth of clinically relevant knowledge of organ site-specific adaptations of melanoma metastases and their possible influence on therapeutic responses. This project will derive this knowledge through comprehensive analysis on not only melanoma lesions at distinct organ sites but also their adjacent and non-adjacent normal organ tissues from warm autopsies. Through integrative genomic and transcriptomic analysis of triplets of tumor, adjacent normal and non-adjacent normal specimens, this study sets out to dissect the co-evolution of the tumor and its host organs. The preliminary analyses have already revealed several pathway activations that may be related to MAPK inhibitor (MAPKi) or immune checkpoint blockade (ICB) resistance in the brain, liver and spleen metastases.
Aimi ng for a larger set of specimens, the researchers will assess the tumor heterogeneity (at the genomic, transcriptomic and pathway activation levels), their association with metastatic growth and MAPKi/ICB response patterns in each metastatic organ. In parallel, the research team will examine the tumor-adjacent normal tissues' cellular composition and pathway activations. These will also be correlated with organ-specific tumor growth and treatment resistance. The PI's experiences in large omic integration analyses of MAPKi and ICB resistant tumors will be a tremendous asset for the success of the proposed work. This study is expected to discover and validate heretofore unknown determinants of organ-specific metastasis in melanoma and novel mechanism(s) of resistance to MAPKi and ICB.

Public Health Relevance

Cancer patients die of metastasis, and this advanced stage of disease is especially aggressive in metastatic melanoma. Melanoma metastasizing to distinct organs not only adapts to these organs' environment but also co-opts organ site-specific niches to thrive and evade therapies. Comprehensive study of organ-specific melanoma biology will enable a clearer understanding on the differential prognosis and therapy response associated with distinct metastatic organs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA236910-01A1
Application #
9886055
Study Section
Mechanisms of Cancer Therapeutics - 1 Study Section (MCT1)
Program Officer
Hughes, Shannon K
Project Start
2020-05-01
Project End
2025-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095